Anticholinergic medications are frequently used in older adults to manage a wide range of chronic diseases. Anticholinergic burden associated with the use of multiple medications with anticholinergic effects is cumulative within an individual, and older adults are particularly susceptible to the adverse effects of these medications. These include dry mouth resulting in poor oral health, constipation, urinary retention and confusion. Use of anticholinergic medications has been associated with impaired cognitive and physical function, increased risk of falls, vascular events and hospitalisation. Consideration of anticholinergic burden is an important component of medication management for older adults. Several measures have been developed and validated to quantify anticholinergic burden, such as the Anticholinergic Drug Scale, Anticholinergic Risk Scale and the Anticholinergic Cognitive Burden scale. However, the evidence for translation of these measures into clinical practice is limited. This narrative review provides a brief clinical overview of the pharmacology of anticholinergic medications in the context of older adults, summarises approaches to measure anticholinergic burden, reviews recent evidence of the clinical impact of anticholinergic medications and discusses deprescribing strategies to manage anticholinergic burden for older adults in clinical practice.
INTRODUCTION
Anticholinergic medications are medications that block acetylcholine receptors in central or peripheral tissues, either as an intended therapeutic effect or as unwanted effects. Medications with anticholinergic effects are commonly used by older adults for a wide variety of clinical conditions, including Parkinson's disease, depression, chronic obstructive pulmonary disease, psychosis, urinary incontinence and allergic rhinitis. An Australian cohort study estimated that 22-37% of adults aged 60 years or older were prescribed one or more anticholinergic medications. 1 Depending on the study setting and method of measuring anticholinergic burden, studies conducted in other countries report a 21-50% prevalence of use of anticholinergic medications. 2, 3 Adverse effects commonly associated with anticholinergic medications include dry mouth, constipation, urinary retention, cognitive impairment, and functional impairment (reduced ability to perform activities of daily living). Due to changes in physiological and pharmacological processes, anticholinergic adverse effects may be more pronounced in older adults compared with younger adult populations. 4 Additionally, other patient-and prescribing-related factors, such as polypharmacy, multimorbidity and geriatric syndromes, may further impact on the presentation and recognition of anticholinergic adverse effects in older adults.
Anticholinergic burden is the cumulative effect on an individual of taking one or more medications with anticholinergic activity. Several measures have been developed to quantify anticholinergic burden in older adults. These measures include and weigh anticholinergic medications differently. Anticholinergic burden measures have also been incorporated into interventions designed to reduce prescribing of anticholinergic medications. However, the potential for application of these measures to trigger clinical review and appropriate withdrawal of anticholinergic medications in older adults in practice varies between measures and clinical situations.
The aim of this narrative review is to provide a brief clinical overview of the pharmacology of anticholinergic medications in the context of older adults, summarise approaches to measure anticholinergic burden, review recent evidence of the adverse clinical impact of anticholinergic medications, and discuss withdrawal or deprescribing strategies to manage anticholinergic burden for older adults in clinical practice.
ANTICHOLINERGIC MEDICATIONS AND AGEING
Anticholinergic medications (also known as atropinic drugs or muscarinic antagonists) act on muscarinic receptors to block the effects of parasympathetic nerve activity. Muscarinic receptors are located throughout the central and peripheral nervous systems. There are five subtypes denoted as M1, M2, M3, M4 and M5 muscarinic receptors. Anticholinergic medications inhibit acetylcholine-mediated responses by competitively binding to these receptors. 5 Most anticholinergic agents are tertiary or quaternary ammonium compounds, making them highly specific at muscarinic receptors to competitively antagonise the effects of acetylcholine, as well as being lipid soluble to allow for easy penetration across the blood-brain barrier after absorption and first-pass metabolism from the gut, lungs or conjunctiva. 6 The potential for medications to cause anticholinergic adverse effects is dependent on the affinity of the medication to the muscarinic receptor subtypes, and their capacity to cause central anticholinergic effects depends on their ability to cross the blood-brain barrier. Physiological and pathological processes associated with ageing change the size and function of organs that are responsible for the pharmacokinetics and pharmacodynamics of anticholinergic medications. Pharmacokinetic changes include reduced activity of metabolic enzymes, reduced plasma protein concentrations and reduced liver and renal function. This results in changes to the volume of distribution, metabolism, elimination and end-organ sensitivity to medications. 7 Changes to pharmacodynamic responses include altered drug-receptor affinity, changes to post-receptor events such as signals from the cell membrane receptor to the cell nucleus, and age-related decline in central cholinergic transmission. These changes may reduce concentrations at which drugs are effective or toxic. For example, due to pharmacokinetic and pharmacodynamic changes, older adults may respond more slowly to amitriptyline (because amitriptyline undergoes extensive metabolism in the liver to nortriptyline), have higher plasma concentrations of amitriptyline and experience more side effects with amitriptyline compared with younger adults. 8 Failure to consider age-related pharmacokinetic and pharmacodynamic changes when prescribing and monitoring anticholinergic medications for older adults may increase risk of adverse effects. These include pronounced central nervous system adverse effects such as cognitive impairment, confusion, delirium and falls, and peripheral adverse effects like constipation, dry eyes and urinary retention. 8 The proposed mechanisms of centrally mediated adverse effects relate to the pharmacological action of these medications. For example, mydriasis, dry eyes and the inability to accommodate changes in light exposure may impair near vision and could lead to an increased risk of accidents, including falls. The central anticholinergic effects of sedation and cognitive impairment also contribute to risk of falls and global functional decline. 9 
MEASUREMENT OF ANTICHOLINERGIC BURDEN
Recognition of the negative impact of anticholinergic medications on older adults has led to the development and validation of several measures to quantify anticholinergic burden (Figure 1 ). 20 The main difference between the DBI and other anticholinergic scales is that anticholinergic (and sedative) burden is calculated using a pharmacological model accounting for the prescribed dose of medications.
Analysis of the methods used to develop these anticholinergic burden scales demonstrates some similarities and differences. Most scales provide a list of anticholinergic medications and a rank of low to high risk based on anticholinergic activity. However, variability in how anticholinergic medications are defined and classified means there is variation in the number of medications included in the various scales ( Figure 1 ). Some scale developers used serum anticholinergic activity to define anticholinergic medications, some used expert consensus, and some used assessment of the drug monograph and pharmacological action. Some scales incorporate drugs with minor anticholinergic activity (e.g. digoxin, ranitidine) while others do not. There are also differences in how anticholinergic medications are scored and summed to create an overall burden score.
In a recent New Zealand study where anticholinergic medication exposure was calculated using nine published scales, there were substantial differences in the estimation of anticholinergic exposure and the corresponding association with adverse clinical outcomes such as hospital admissions, length of hospital stay, falls and general practitioner visits. 21 Lampela et al.
demonstrated that the ADS and AAS anticholinergic scales 12, 15 were more predictive of anticholinergic adverse events in community-dwelling people aged 75 years and older than the ARS and serum anticholinergic activity. List based on serum anticholinergic activity. 15 
§
Number of medications included in the DBI calculation includes anticholinergic and sedative medications, and varies according to each country's formulary at the time of the study. The number reported here is the number of anticholinergic and sedative medications that a cohort of 2172 older adults were exposed to in the USA.
Several systematic reviews have investigated associations between anticholinergic burden, measured using a range of scales, and clinical outcomes. [22] [23] [24] [25] [26] Almost all of these reviews arrived at the conclusion that considerable variation exists among the anticholinergic scales and there is no gold standard tool for measuring anticholinergic burden. Two systematic reviews found that higher anticholinergic burden was associated with poorer cognitive and physical function, and falls. 22, 24 One review, by Cardwell et al., reported that any of the anticholinergic burden measures they assessed were suitable for translation to clinical practice, while another, by Salahudeen et al., established a 'composite rating scale to categorise anticholinergic activity medicines' that combines anticholinergic medications and their activity from seven published scales and ranks anticholinergic activity from high to low. 22, 24 It is important to consider the evidence-base when selecting an anticholinergic burden scale to use in practice to improve clinical outcomes relevant to older patients.
ANTICHOLINERGIC ADVERSE EVENTS IN OLDER ADULTS
Recent systematic and narrative reviews have reported that anticholinergic medications are associated with increased risk of functional and cognitive decline, institutionalisation and falls in older adults. 27, 28 In a metaanalysis, Ruxton et al. demonstrated that there is an increased risk of falls, cognitive impairment and allcause mortality in older adults when anticholinergic medications were measured as either a drug class or using anticholinergic burden scores. 28 Results from published studies are challenging to synthesise due to different measures of exposure and outcomes between studies. [22] [23] [24] [25] [26] The evidence needs to be interpreted with caution as studies have shown inconsistent associations between anticholinergic burden and certain outcomes, such as mortality. 29 For instance, a recent prospective cohort study of hospitalised patients aged 75 years and older associated anticholinergic medications with mortality. 30 In contrast, anticholinergic load measured using the ARS was not associated with mortality in residents of long-term care facilities in Finland. 31 These differences may be due to different approaches used to measure anticholinergic burden, study design and setting, inadequate adjustments for confounding, and a lack of consistency in defining anticholinergic medications and outcomes. However, expert consensus criteria for inappropriate prescribing in older people, such as the Beers Criteria 32 and STOPP criteria, 33 suggest that many anticholinergic medications should be avoided in older people, especially for people with known cognitive impairment. The consequences of a fall in older adults can be severely debilitating and include hip fracture, hospitalisation, depression, and lead to poor quality of life. In a recent prospective cohort study of post-menopausal women, anticholinergic medication use defined using the ADS, was associated with a 1.5 times increased risk of recurrent falls. 34 This is consistent with previous studies associating anticholinergic medication use with falls. 35 Regarding cognitive function, a retrospective study of Australian war veterans reported that anticholinergic medication use (measured using the ADS and ARS) was associated with risk of hospitalisation for confusion or dementia. 36 Risacher et al. recently demonstrated that increased brain atrophy, dysfunction and clinical cognitive decline evident from cognitive testing and neuroimaging, was associated with anticholinergic medication use (measured using the ACB) in two longitudinal studies of older adults.
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Apart from the effects on physical and cognitive function, anticholinergic medication use has recently been demonstrated to affect other disease states. Secondary analysis of data collected for a large cross-sectional study in Finland suggested that use of anticholinergic and sedative medications may increase risk of dental caries in older people. 38 Another study analysed the data from several large randomised controlled trials and reported that inhaled anticholinergic medications, such as ipratropium and tiotropium, have the potential to increase the risk of serious cardiovascular events, including mortality, when used in the treatment of chronic obstructive pulmonary disease. The authors of this study stated that these associations have been underreported in randomised controlled trials and medication product information. 39 Additionally, in a nested casecontrol study, anticholinergic medication use by older adults was significantly associated with a greater risk of developing community-acquired pneumonia, compared with no use (odds ratio 1.65, 95% confidence interval 1.20-2.28). 40 These previously unrecognised associations could significantly impact on medical and medication management of older adults. 62 RCT, n =
115
The provision of patient-specific information about DBI to GPs DBI decreased in 32% (6/19) in intervention group and 19% (6/31) in control group
Clinician-rated Anticholinergic
Score (Cr-AS) 63 Yeh et al. 65 Cluster RCT, n = 227 Educational intervention targeting assisted living facility nurses to recognise harmful medications No significant impact on anticholinergic medication use Anticholinergic Risk Scale (ARS) 19 Tay et al. 'prescribing cascade', when a new medication is prescribed to 'treat' an adverse reaction to another medication, or a failure to reduce anticholinergic burden in older adults. 42, 43 Several interventions have been reported in the literature aimed at reducing anticholinergic burden in older adults (Table 1) . These include medication review, academic detailing, education of healthcare practitioners, and computerised clinical decision support systems (CCDSS). While the impact of these interventions on anticholinergic burden has been demonstrated, evaluation of impact on clinical outcomes is rarely reported.
A recent retrospective study investigating the impact of a pharmacist-led medication review on anticholinergic burden, reported that between 36% and 67% of nursing home residents were prescribed an anticholinergic medication at baseline, and pharmacists' recommendations significantly reduced the mean anticholinergic burden measured by seven anticholinergic scales. 44 This is consistent with other retrospective studies where medication review interventions have demonstrated a reduction of the DBI scores of older adults. 45, 46 In a Dutch randomised clinical trial comparing the effect of individual and group educational visits to general practitioners and pharmacists to discuss prescribing of highly anticholinergic antidepressants in older people, a 26% reduction in the rate of starting highly anticholinergic antidepressants in older adults was reported (intent-to-treat analysis). 47 Computerised clinical decision support systems (CCDSS) are defined as systems that apply algorithms to individual patient data to generate suggested actions intended to improve clinical decision making and optimise health outcomes. 48 With the advancements of technology, CCDSS are increasingly being utilised in interventional studies where published anticholinergic burden scales are incorporated into new or existing software to aid medication management of older adults ( Table 1 ). The majority of the studies incorporating validated anticholinergic scales such as the ABC, ACB and ARS into CCDSS demonstrated a significant reduction in prescribing anticholinergic medications in older adults. However, a recently published randomised controlled clinical trial of a multifaceted CCDSS intervention in hospitalised older adults with cognitive impairment demonstrated no improvement in the process of care; the intervention involved a CCDSS that alerted physicians on the presence of cognitive impairment, recommended referral to a geriatric consult and suggested discontinuation of catheterisation, physical restraints and anticholinergic medications. 49 A sub-analysis of this study, found that patients transferred to intensive care for delirium also did not see a change in prescribing patterns or decreasing incidence of delirium with the intervention. 50 The main difference between these studies and others is that the CCDSS intervention did not involve a previously validated anticholinergic scale. Future studies should consider combining validated scales with multifaceted and multidisciplinary interventions to change prescribing and clinical outcomes in older adults. • Reduction of the dose by 50% every two weeks, then ceasing after two weeks on the minimum dose, with monitoring for recurrence of target symptoms, behaviours or emergence of new ones • The longer a medication has been prescribed, the slower the rate of withdrawal should be (unless there are concerns over current ADRs) 72 Anti-parkinsonian anticholinergics (e.g. benztropine, benzhexol, biperiden)
• No clearly defined deprescribing strategies available • The dose should be tapered gradually to avoid withdrawal symptoms that may present as an acute exacerbation of parkinsonism and/or anticholinergic discontinuation syndrome 73, 74 Antimuscarinics (e.g. oxybutynin, solifenacin)
• No clearly defined deprescribing strategies available • Regularly review effectiveness and adverse effects (especially cognitive function) of medication treatment.
Cease if there is no improvement in urinary symptoms after 4 weeks of starting an antimuscarinic 74, 75 • Abrupt cessation in long-term users may induce anticholinergic discontinuation syndrome 73 • An option to aid dose reduction may be to consider switching the formulation (if available) (i.e. oral to transdermal)
Antihistamines (e.g. promethazine)
• Abrupt cessation can be associated with mild anticholinergic withdrawal symptoms; 76 however, antihistamines are rarely needed long-term 73 • Where appropriate, consider switching to alternatives with fewer anticholinergic effects such as non-sedating antihistamines or intranasal corticosteroids 77 TCAs (e.g. amitriptyline, doxepin, trimipramine) and SSRIs
• Abrupt cessation should be avoided. Various sources state differing tapering regimens: o reducing the dose by 25% per day 74 o reducing the dose by 50% every week until the daily dose is half of the lowest unit strength available, and then stopped after 1 week, 76 • Special note for fluoxetine: gradually stopping fluoxetine (to avoid withdrawal symptoms) is usually unnecessary due to its long half-life 74 ADR = adverse drug reaction; BPSD = behavioural and psychological symptoms of dementia; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant. a An understanding of the medication's pharmacokinetic and pharmacodynamic profile may guide tapering regimens. More frequent and severe withdrawal symptoms have been associated with medications with a shorter elimination half-life, higher doses and longer duration of treatment at therapeutic doses (e.g. ≥5-8 weeks).
76,78
b Based on key Australian consensus-based references.
71-77

DEPRESCRIBING ANTICHOLINERGIC MEDICATIONS
In a recent review of deprescribing definitions, it was proposed that deprescribing is the process of withdrawal of an inappropriate medication, supervised by a healthcare practitioner with the goal of managing polypharmacy and improving outcomes. 51 In Australia, a deprescribing algorithm for optimising medications was recently proposed. 52 Other Australian online tools are also freely available to guide healthcare practitioners to deprescribe certain classes of medications. 53, 54 Deprescribing is usually conducted after consideration of therapeutic goals, benefits and risks for the patient. 55 Given the growing evidence of negative consequences of anticholinergic medications in older adults, deprescribing anticholinergics may be considered as part of the comprehensive medication management of older adults. A recent systematic review of the feasibility and effect of deprescribing one or more medications in older adults suggested that deprescribing appears to be feasible, generally safe and may have some health benefits for older adults. 56 For instance, a randomised controlled trial involving community-dwelling older adults in New Zealand demonstrated that withdrawal of psychotropic medications, including antidepressants and antipsychotics, significantly reduced the risk of falling. 57 Medications with anticholinergic effects exist within various pharmacological classes (Table 2) , making it difficult to recognise anticholinergics and decide whether to cease or taper doses of any given anticholinergic medication. 41 In his seminal deprescribing article published in 2003, Woodward 58 provided brief considerations for anticholinergic medications that can assist in establishing a deprescribing regimen, which included ceasing with awareness of adverse withdrawal effects. Abruptly ceasing anticholinergic medications may sometimes lead to anticholinergic discontinuation syndrome characterised by nausea, sweating, urinary urgency, anxiety, tachycardia, orthostatic hypotension and apparent deterioration of sleep quality. 59 The pharmacokinetics, pharmacodynamics and total anticholinergic burden of medications should always be evaluated before deciding on cessation or tapering withdrawal. We reviewed various evidence-based resources to summarise practical information on how to deprescribe anticholinergic medications (Table 3 ). There was a lack of clearly defined deprescribing strategies for medication classes that have anticholinergic properties. Overall, the decision to cease or taper doses of anticholinergic medications is dependent on the clinical impact of the anticholinergic adverse events in the individual, duration of therapy, pharmacology of the anticholinergic medication, management of co-existing conditions and monitoring of adverse withdrawal effects.
CONCLUSION
Anticholinergic medications are frequently used by older adults to manage a wide range of chronic conditions, often in combination, resulting in cumulative anticholinergic burden. Evidence of anticholinergic adverse events in older adults is growing, and various interventions, including pharmacist review and integration of anticholinergic burden measures within CCDSS demonstrate significant reduction of anticholinergic prescribing. Deprescribing anticholinergic medications involves careful cessation or tapering, with consideration of the specific clinical scenario and the pharmacology of the medications. Future deprescribing trials may provide further guidance on the implementation of interventions and outcomes of deprescribing anticholinergic medications in clinical practice.
